Myelodysplastic syndrome: A review

More Pooja Navanath and Swapnil Mhaske

Abstract

The purpose of this review is to provide the most recent data on myelodysplastic syndrome. Haematopoietic disorders, which are stages in the process of leukaemia development, describe the myelodysplastic syndromes (MDS). It is characterized by aberrant blood cytopenias and blood cells with unusual appearances, such as macrocytic red blood cells and hypogranular neutrophils with nuclear hyper/hypo segmentation. Due to the disease's complex pathogenetic characteristics, diverse phases, and patients' typically advanced ages, MDS presents therapeutic challenges. Innate stem cell lesions, stromal defects caused by cellular/cytokine activity, and immunologic abnormalities are the underlying causes of the cytopenias and evolutionary potential in MDS.

The recent biospecific medications that may be able to stop abnormalities are reviewed in this article. Their annual crude incidence ranges from 2.1 to 12.6 cases per 100,000 individuals. We currently deal with incidence rates of between 15 to 50 cases per 100,000 individuals per year among the age group that is most impacted, people older than 70 years. The Cancer.Net Editorial Board authorized it on February 2, 2022. Each year, MDS is identified in about 10,000 persons in the United States. In adults under 50, MDS is uncommon. The number of people receiving an MDS diagnosis each year is projected to rise as the population of the United States gets older. According to recent research on the impact of myelodysplastic syndromes (MDS) as follows:

1. MDS can affect Quality of life.
2. Emotional disturbance from MDS was often viewed as more problematic than the physical impact; emotional reactions included shock, anger, depression, and anxiety. Frustration The overall incidence is 4 in 1 lakh rising to more than 30 in 1 lakh.

Keywords: Myelodysplastic syndromes, cytopenias, old age, cytopenias, biospecific drugs, quality of life

Introduction

The majority of MDS patients could develop acute myeloid leukemia in the future (AML). A reduction in the quantity of red blood cells (RBC), platelets, and white blood cells is one of the clinical symptoms (WBC). The disease's progression can change. As there is no survival advantage with the treatment of asymptomatic, low-risk patients, not all patients initially need treatment. Patients with symptoms, such as those who frequently need blood transfusions, are the only ones who receive treatment. Numerous variables, including the degree of cytopenias, the proportion of blasts in the peripheral blood and bone marrow, and karyotype, affect prognosis and overall survival.

What is MDS?

Myelodysplastic syndromes are a rare group of disorders in which your body no longer makes enough healthy blood cells. Sometimes hear it called a “bone marrow failure disorder.”

Etiology

Primary MDS

Affects roughly 1 in 500 patients between the ages of 60 and 75 and is mostly an aging-related disease. Idiopathic conditions are the norm. Although MDS is frequently referred to as a “preleukemic” condition, there is only a 25%–30% chance that it will develop into acute myeloid leukemia (AML). The discovery of distinctive gene deletions and translocations indicative of both the MDS subtype and the AML subtype highlights the probability of similar mechanisms of clonal myeloid stem cell damage in both disorders.
Secondary MDS
People who have previously been exposed to chemotherapy, radiation, or organic compounds like benzene are more likely to develop secondary MDS. This condition affects 10% to 15% of all identified MDS patients and can strike at any age. Treatment-related MDS is defined as MDS that develops months to years following prior chemotherapy, ionizing radiation, radiolabelled antibody therapy, or stem cell transplantation for malignancy (t-MDS). These patients have recently been reclassified as therapy-related acute myeloid leukemia and are currently being treated as such since t-MDS frequently develops quickly into a more severe disease.

Clinical Features
Many patients are asymptomatic, with the illness being discovered incidentally when a CBC is performed for other purposes. Patients have profound symptoms and complications from the illness.

Physical effects
These problems may persist in a fairly steady state for months, even years.
1. Headache, light headedness, shortness of breath, paleness, and fatigue. These result from anemia.
2. Recurrent pneumonias because of neutrophil dysfunction.
3. Bleeding – because of platelet dysfunction.
4. Dysplasia
5. Skin lesions with fever.
6. Susceptibility to infections, especially in the lungs, throat, sinuses, and skin, as well as mouth or ear infections or periodontal disease. These result from neutropenia, which is shortage of a specific type of white blood cell called a neutrophil.
7. Bruising, nosebleeds, and pinpoint red spots or rashes on the skin. These result from thrombocytopenia, which is a shortage of blood platelets.

Psychological effects
1. Distress
2. Frustration
3. Confusion

WHO classification of MDS Syndrome
World Health Organization (WHO) classification of myelodysplastic syndrome (MDS) in 2016

MDS with ring side roblasts
(MDS-RS): associated with mutations in the splice some gene SF3B1, overall favourable prognosis, must not meet criteria for isolated del(5q), blasts < 5% BM, < 1% PB, no Auer rods. MDS-RS and single lineage dysplasia (former RARS): 1 dysplastic lineage, 1 - 2 cytopenias. MDS-RS and multiline age dysplasia: 2 - 3 dysplastic lineages, 1 - 3 cytopenias

MDS with single lineage dysplastic
- 1 dysplastic lineage, 1 - 2 cytopenias
- Blasts < 5% BM, < 1% PB, no Auer rods
- Does not meet criteria for MDS-RS or MDS with isolated del(5q)

MDS with multiline age dysplasia
- 2 - 3 dysplastic lineages, 1 - 3 cytopenias

MDS with isolated del (5q)
The only cytogenetic abnormality that defines a subtype
- Okay if 1 additional cytogenetic abnormality as long as NOT monosomy 7 or del(7q)
- None or any ring sideroblasts, 1 - 3 dysplastic lineages, 1 - 2 cytopenias
- Blasts < 5% BM, < 1% PB, no Auer rods
- Generally good prognosis unless TP53 mutated

MDS with excess blasts: 1-3 dysplastic lineages, 1-3 cytopenias, none or any ring sideroblasts
- MDS-EB-1: blasts 5-9% BM or 2-4% PB, no Auer rods.
- MDS-EB-2: blasts 10-19% BM or 5-19% PB or Auer rods

MDS, unclassifiable
3 different ways to arrive at this diagnosis
- MDS-U with 1% blood blasts: 1-3 dysplastic lineages, 1-3 cytopenias, none or any ring sideroblasts, < 5% BM blasts
- MDS-U with SLD and pancytopenia: 1 dysplastic lineage, pancytopenia, none or any ring sideroblasts, blasts < 5% BM, < 1% PB, no Auer rods
- MDS-U based on defining cytogenetic abnormality: 0 dysplastic lineages, 1-3 cytopenias, <15% ring sideroblasts, blasts < 5% BM, < 1% PB, no Auer rods; MDS defining cytogenetic abnormality.

Refractory cytopenia of childhood
Provisional entity

Myeloid neoplasms with germline predisposition
Specific underlying genetic defect or syndrome should be listed as part of the diagnosis

Investigation that can be done at a routine hematology laboratory
Routine Haemogram
This may be done in an automated counter ensuring good quality control measures. In MDS this may show cytopenias which may be unilineage or multiline age. Cytopenias as defined in International Prognostic Scoring System (IPSS)

Peripheral Smear examination
RBC: Generally normocytic or macrocytic.
WBC: Leukopenia due to neutropenia is a common finding. The characteristic features of dysplasia in the form of pseudo Pelger-Huet anomaly or hypo granulation may be seen. Occasionally it may show presence of myeloblast and myelocytes.
Platelets: Platelets are reduced in most of the patients. Presence of normal or raised platelets may be seen especially in association 5q-syndrome
[Note: Whenever an elderly patient presents with cytopenias (uni, bi, or pancytopenia) and there are no other explanations for it, a suspicion for the diagnosis of MDS should always be kept in mind. Additionally, a sample for cytogenetics should be sent whenever a bone marrow procedure is performed.]

Bone Marrow examination
Bone marrow examination by an experienced
hematopathologist is must for diagnosis of MDS. Both bone marrow aspirate and trephine biopsy should be examined.

Treatment
Supportive therapy
Supportive care includes the use of blood and platelet transfusions for people with dangerously low red blood cell and platelet counts. Antibiotics can be used to treat infections. People with MDS may also benefit from taking injections such as erythropoetin (Procrit®) and darbepoetin (Aranesp®). These drugs stimulate the bone marrow to produce red blood cells. Medications that coax the bone marrow to produce more white blood cells include granulocyte colony-stimulating factor (Neupogen®) and pegfilgrastim (Neulasta®). Treatments may help improve blood counts temporarily and reduce or eliminate symptoms from low blood counts. They do not fix the underlying cause of MDS.

Intensive therapy
Patients with high-risk MDS for aggressive AML-based chemotherapy. These standard regimens are designed to eradicate rapidly proliferating blast cells, not dysfunctional MDS cells, and therefore unsurprisingly are associated with high relapse rate (with 12-18 months) and no significant prolongation of overall survival, even in pt who achieve remission. As in other hematologic stem cell disorder, the only curative therapy is allogenic stem cell transplantation, ideally performed at complete remission.

Targeted Therapeutic agent
A targeted therapy is one that is designed to treat the cancer cells and minimize damage to normal, healthy cells. Cancer treatments that “target” cancer cells may offer the advantage of reduced treatment-related side effects and improved outcomes.

[Revlimid]: Revlimid is a brand-new kind of medication known as an Immuno-modulatory medication that controls the immune system. Revlimid is expected to have a number of anticancer effects, including the elimination of aberrant white blood cells, the reduction of inflammation, and the inhibition of the development of new blood vessels.

Areas of active investigation aimed at improving the treatment of MDS include the following:
- Antithymocyte globulin (ATG)
- Gleevec® (imatinib methylate)
- Zarnestra (tipifarnib)

Prospectus for the future
Stem cell biology is a rapidly evolving science. A number of disorders affecting both hematopoietic and non-hematopoietic stem cells have been linked to specific molecular pathways that are disrupted, as shown by research on how hematopoietic stem cells operate in bone marrow failure syndromes. These findings are also advancing our knowledge of the intricate interactions between AA, PNH, and MDS. Understanding stem cell plasticity and the role of the stem niche in disease regulation may lead to promising new treatment options for a variety of diseases. When patients with primary hematologic diseases are in need of allogenic stem cell transplantation but cannot find other HLA-matched marrow donors, umbilical cord blood stem cells are a viable source of donor cells. For older patients with primary bone marrow failure, non-myeloablative stem cell transplants with low-dose conditioning and immunosuppressive regimes are an emerging therapy option.

Conclusion
Patients with MDS bear a heavy load of distress. High level of distress, with the most frequently mentioned problem being physical symptoms, second, rather than the prognosis for MDS, distress is more closely linked to receiving treatments and services, such as blood transfusions.

Conflict of Interest
Not available

Financial Support
Not available

References
9. Davidson’s principles & practice of medicine, 2 oth edition, EL SEVIER; 2

How to Cite This Article

Creative Commons (CC) License
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.